DeepUll Raises €13M in Series B Financing
- DeepUll, a Barcelona, Spain-based medical diagnostics company, raised €13M in Series B funding
- The round was led by Innvierte, with participation from Kurma Partners, Alta Life Sciences, UI Investissement, and Axis Participaciones Empresariales
- The company intends to use the funds to progress the development of its sepsis recognition platform towards the market
- The company is a medical diagnostics company developing culture-free diagnostic solutions for sepsis and acute infections
- The company’s sepsis product is designed to detect more than 250 different pathogens and about 15 resistance genes in one hour starting from 10mL of whole blood
- The product will generate phenotypic antimicrobial susceptibility results in about eight hours, without requiring a positive blood culture
